FCF Fox Company Finance GmbH is delighted to publish the brand new “FCF Biotech Enterprise Capital Monitor – USA 11/2021”.
The Monitor is a month-to-month printed overview of enterprise capital developments within the US-Biotech sector.
As of the top of November 2021, we determine the next present VC developments within the US-Biotech sector:
- In 2021, total Biotech funding within the USA has reached USD 30,945m to this point
- Prime 5 offers exceed USD 400m every, largest transaction amounted to USD 735m in Treeline Biosciences, Inc.
- Logos Capital (USA) leads the Prime 5 Buyers (by deal quantity), adopted by ARCH Enterprise Companions (USA) and OrbiMed (USA)
- Oncology dominates as the highest indication
To entry the total report, please click on right here.
By Dr. Mathias Schott and Sebastian Sommer